WuXi STA, an international leader in the Contract Research, Development, and Manufacturing Organization (CRDMO) sector, recently unveiled a high potency (HP), fully automated sterile injectable manufacturing line. The line, situated in Wuxi City, China, significantly boosts the company’s manufacturing capabilities and capacity for injectable dosage forms.
The design of the manufacturing line minimizes human intervention and thus reduces the risk of cross-contamination. The entire process adheres to the strictest Occupational Exposure Limits (OEL) as low as 10 ng/m3. Such adherence to safety and environmental regulations exemplifies WuXi STA’s commitment to quality assurance in its manufacturing processes.
The company is also eyeing further expansion. By 2024, it intends to add two more injectable manufacturing lines at the Wuxi City site, demonstrating its dedication to industry growth and innovation. This drive towards continuous development and patient care is echoed by Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, who pledges the company’s commitment to “accelerating pharmaceutical development and bringing new therapeutics for patients worldwide.”
